Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.

This peer reviewed manuscript, entitled, "Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis," provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women.  Kim Henriksen, MSc, PhD, Head of Musculoskeletal Diseases at Nordic Bioscience served as the lead author of the article, which was jointly prepared by authors from Nordic Bioscience, Unigene Laboratories, the Center for Clinical and Basic Research (CCBR) and GlaxoSmithKline (GSK).

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We are extremely pleased that a peer-reviewed article detailing the positive Phase 2 results from our oral PTH program was published in such a prestigious scientific journal as Bone.  The data and analysis once again demonstrate the strength of Unigene's proprietary oral peptide drug delivery technology and the clinical potential and commercial viability of our oral PTH analog.  I would like to extend my congratulations to Dr. Henriksen for leading the publication effort and to the entire team of contributors from Nordic Bioscience, CCBR, GSK and Unigene for their tremendous wor
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported ... June 28, 2014.  , Revenues were $10.6 million ... million in the 2013 second quarter and up sequentially from ... the first six months of 2014 were $20.9 million, up ... last year. , Gross margin for the quarter was ...
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2
... 2011 Surgical Information Systems ("SIS") announced today ... management systems as a key component of the ... Healthcare Information and Management Systems Society, February 20-24 ... presentations and solution demonstrations, SIS will showcase the ...
... Va., Feb. 17, 2011 Radiologic Associates of ... Campaign to increase awareness of opportunities to lower radiation ... of the Alliance for Radiation Safety in Pediatric Imaging.  ... additional training in ways to reduce radiation exposure, especially ...
Cached Medicine Technology:Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 2Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 3Radiologic Associates of Fredericksburg Announces Image Gently Campaign to 'Child Size' Doses for Children 2
(Date:8/1/2014)... Medicine in St. Louis helps explain why brain tumors ... harmful than similar tumors in females. For example, glioblastomas, ... as often in males, who suffer greater cognitive impairments ... The researchers found that retinoblastoma protein (RB), a protein ... in male brain cells than in female brain cells. ...
(Date:8/1/2014)... Parker Waichman LLP, a national law ... by defective medical devices and drugs reports that Johnson ... surgical power morcellator devices used for the removal of ... spread of cancer associated with power morcellators, according to ... , Johnson & Johnson had previously ceased the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Stryker ... wake of the 2012 Rejuvenate and ABG II ... in New Jersey’s Bergen County Superior Court, Bernstein ... the proceeding, the Court has issued a ... any and all hard copy and electronic materials ...
(Date:8/1/2014)... News) -- Almost 140 people die every year ... United States. But there are several simple ... injury prevention coordinator at Cincinnati Children,s Hospital Medical ... medical center news release. "As families begin ... important for parents and children to go over ...
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Expert Offers School Bus Safety Tips 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4
... MS ... end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported ... Move it to create a world free of MS! , ... New York, NY (Vocus) March 8, 2010 -- MS Awareness Week March 8-14 ...
... ... ... ... ...
... Researchers at the ... better than anything that’s come before. With the new technology they’ve developed, the scientists produce ... and the major arteries around it. , ... Madison, WI (PRWEB) March 8, 2010 -- What does the racing heart of ...
... , ... national distributor of medical equipment and supplies announced today they have been named as ... will also offer the complete line of Gendron bariatric care medical equipment to healthcare ... ...
... CITY, March 8, 2010 University of Utah engineers developed a ... and others precisely control scalpels, brushes and tools over a wider ... "We,ve ... for aiding people in performing precision tasks with their hands such ...
... School of Medicine have devised a software algorithm that could ... sample into its different cell types and detect medically important ... In a study to be published online March 7 ... had successfully used the new technique to pinpoint changes in ...
Cached Medicine News:Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 2Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 3Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 4Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 5Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 6Health News:I'm Not Crazy...I'm Just Not You 2Health News:I'm Not Crazy...I'm Just Not You 3Health News:I'm Not Crazy...I'm Just Not You 4Health News:I'm Not Crazy...I'm Just Not You 5Health News:I'm Not Crazy...I'm Just Not You 6Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 2Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 3Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 2Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 3Health News:A high-tech handrest 2Health News:A high-tech handrest 3Health News:A high-tech handrest 4Health News:A high-tech handrest 5Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 2Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 3Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 4
... offers a new and efficient method applied ... Springing from ongoing research and development with ... just a light source, but rather a ... represents new horizons in pulsed-light-based technology, the ...
Auto Refkeratomoeter...
The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophistica...
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: